Literature DB >> 10086997

Prostaglandin E-prostanoid-3 receptor activation of cyclic AMP response element-mediated gene transcription.

L P Audoly1, L Ma, I Feoktistov, S K de Foe, M D Breyer, R M Breyer.   

Abstract

The prostaglandin E-prostanoid (EP)3 receptor signals primarily through the inhibitory G protein Gi, thereby decreasing intracellular cAMP levels. To study the signal transduction properties of the rabbit EP3 receptor, five splice variants were expressed in HEK293tsA201 cells: 72A, 74A, 77A, 80A and the novel splice variant NT, which lacks the C-terminal sequence. The ability of the EP3 receptor splice variants to modulate expression of a beta-galactosidase reporter gene under the control of a promoter containing cAMP response elements (CRE) was assessed. Each splice variant induced sulprostone-mediated increase in beta-galactosidase enzymatic activity with EC50 ranging from 0.8 nM for the NT splice variant to 3.1 nM for the 77A splice variant. Substitution of either Asp338 with Ala, or Arg329 with Ala or Glu in the 77A splice variant resulted in a loss of receptor-evoked increases in beta-galactosidase activity, whereas substitution of Lys300 with alanine had no effect on signal transduction. These phenotypes correlate with the inhibition of cAMP generation by direct cAMP measurement. Signal transduction was insensitive to pretreatment of cells with pertussis toxin, suggesting that a nonGi/Go pathway is activated by the EP3 receptor. Direct measurement of second messenger levels confirmed that there was no increase in cAMP levels mediated by the 77A splice variant, however, there was a modest increase in intracellular Ca2+. Partial blockade of the reporter activity with kinase inhibitors demonstrates that CRE activation is mediated in part by a Ca2+-dependent kinase pathway. These data suggest that the EP3 receptor signals through a novel cAMP response element binding protein/CRE pathway.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10086997

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Prostaglandin E2 EP3 receptor regulates cyclooxygenase-2 expression in the kidney.

Authors:  Carlos P Vio; Mariana Quiroz-Munoz; Catherina A Cuevas; Carlos Cespedes; Nicholas R Ferreri
Journal:  Am J Physiol Renal Physiol       Date:  2012-05-23

2.  Evidence for the presence of a critical disulfide bond in the mouse EP3γ receptor.

Authors:  Jason D Downey; Charles R Sanders; Richard M Breyer
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-01-12       Impact factor: 3.072

3.  Night eating and obesity in the EP3R-deficient mouse.

Authors:  Manuel Sanchez-Alavez; Izabella Klein; Sara E Brownell; Iustin V Tabarean; Christopher N Davis; Bruno Conti; Tamas Bartfai
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-16       Impact factor: 11.205

4.  The effect of the EP3 antagonist DG-041 on male mice with diet-induced obesity.

Authors:  Ryan P Ceddia; Jason D Downey; Ryan D Morrison; Maria P Kraemer; Sarah E Davis; Jing Wu; Craig W Lindsley; Huiyong Yin; J Scott Daniels; Richard M Breyer
Journal:  Prostaglandins Other Lipid Mediat       Date:  2019-07-02       Impact factor: 3.072

5.  Prostaglandin E2 promotes cellular recovery from established nephrotoxic serum nephritis in mice, prosurvival, and regenerative effects on glomerular cells.

Authors:  Nino Kvirkvelia; Malgorzata McMenamin; Kapil Chaudhary; Manuela Bartoli; Michael P Madaio
Journal:  Am J Physiol Renal Physiol       Date:  2013-01-02

6.  Reduced acute brain injury in PGE2 EP3 receptor-deficient mice after cerebral ischemia.

Authors:  Sofiyan Saleem; Yun Tai Kim; Takayuki Maruyama; Shuh Narumiya; Sylvain Doré
Journal:  J Neuroimmunol       Date:  2009-02-08       Impact factor: 3.478

Review 7.  Emerging roles of PGE2 receptors in models of neurological disease.

Authors:  Katrin Andreasson
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-04-11       Impact factor: 3.072

8.  Extracellular loop II modulates GTP sensitivity of the prostaglandin EP3 receptor.

Authors:  Chandramohan Natarajan; Aaron N Hata; Heidi E Hamm; Roy Zent; Richard M Breyer
Journal:  Mol Pharmacol       Date:  2012-10-18       Impact factor: 4.436

9.  Non-steroid anti-inflammatory drugs, prostaglandins, and cancer.

Authors:  Viola Allaj; Changxiong Guo; Daotai Nie
Journal:  Cell Biosci       Date:  2013-02-06       Impact factor: 7.133

10.  Identification of prostaglandin receptors in human ureters.

Authors:  Matthias Oll; Claudia Baumann; Turang E Behbahani; Alexander von Ruecker; Stefan C Müller; Jörg Ellinger
Journal:  BMC Urol       Date:  2012-12-10       Impact factor: 2.264

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.